The Indian neurological disorder drugs market is anticipated to grow significantly over the forecast period (2020-2026). The key factor that primarily flourishes the growth of the Indian neurological disorder drugs industry includes the rising prevalence of neurological disorders. There is an increased burden of neurological disorders in the country, along with the lack of skilled personnel for the treatment and prescriptions. At the 5th World Heart and Brain Conference held in 2018, it is projected that amongst the 1.36 billion population of India, there were over 30 million people who suffer from neurological disorders, which creates a scope for market growth in the country.
Browse the full report description of "Indian Neurological Disorder Drugs Market Size, Share & Trends Analysis Report by Disorder Type (Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Huntington Disease, and Others), and Forecast 2020-2026" at https://www.omrglobal.com/industry-reports/indian-neurological-disorder-drugs-market
However, there is a lack of neurologists in India as the ratio of one neurologist for more than 1 million population is very low. Along with this, several awareness programs and initiatives regarding neurological disorders may also contribute to the country’s growth in the sector. Besides, the major factor that challenges the growth of the neurological disorder drugs market in India includes the lack of awareness and understanding regarding neurological disorders among the people. Additionally, neurological disorders are also often subjected to various taboos, which heavily impact the lives of patients, and in turn, hampering the neurological disorder treatment market growth in the country.
Market Coverage
Key questions addressed by the report
o Recovery Timeline
o Deviation from the pre-COVID-19 forecast
o Most affected segment
India Neurological Disorder Drugs Market – Segmentation
By Disorder Type
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/indian-neurological-disorder-drugs-market